Trials / Active Not Recruiting
Active Not RecruitingNCT03647878
Study of Cabozantinib as Monotherapy or in Combination With Nivolumab in Patients With Advanced or Metastatic Renal Cell Carcinoma Under Real-life Clinical Setting in 1st Line Treatment.
Prospective Non-interventional Study of Cabozantinib as Monotherapy or in Combination With Nivolumab in Patients With Advanced or Metastatic Renal Cell Carcinoma Under Real-life Clinical Setting in 1st Line Treatment
- Status
- Active Not Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 224 (actual)
- Sponsor
- Ipsen · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of the protocol, is to describe the use of cabozantinib tablets as monotherapy or in combination with nivolumab including the number of dose reductions, dose interruptions and terminations due to (serious) adverse events in subjects with advanced or metastatic renal cell carcinoma (mRCC) treated in real-life clinical setting in 1st line treatment.
Conditions
Timeline
- Start date
- 2018-09-24
- Primary completion
- 2027-09-30
- Completion
- 2027-09-30
- First posted
- 2018-08-27
- Last updated
- 2026-03-31
Locations
82 sites across 2 countries: Austria, Germany
Source: ClinicalTrials.gov record NCT03647878. Inclusion in this directory is not an endorsement.